| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC9972 | ARQ-092(Miransertib) Featured | ARQ 092 is an oral activie, potent and selective AKT inhibitor with IC50 values: 5.0 nM (AKT1); 4.5 nM (AKT2); 16 nM (AKT3). |
|
| DC7820 | ARQ 621 Featured | ARQ 621 is an allosteric, and selective Eg5 mitotic motor protein inhibitor. Phase 1. |
|
| DC8486 | Varlitinib(ARRY-334543) | ARRY-334543 is a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases. |
|
| DC20679 | ARRY-502 | ARRY-502 is an orally bioavailable, potent and selective antagonist of the prostaglandin D2 receptor (CRTh2) for treatment of mild to moderate Th2-driven asthma.. |
|
| DC8181 | Filanesib(ARRY-520) Featured | ARRY-520 is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM. |
|
| DC9495 | ARRY-520 (R enantiomer) | ARRY-520 R enantiomer is the R form of ARRY-520, which is a synthetic, small molecule kinesin spindle protein (KSP) inhibitor with IC50 of 6 nM. |
|
| DC21452 | Artefenomel | Artefenomel (OZ439) is a novel, next-generation antimalarial ozonide that demonstrates high potentcy against P. falciparum in vitro and P. berghei in vivo (K1/NF54, IC50=2.0/3.2 nM).. |
|
| DC21451 | Arterolane | Arterolane (OZ277. |
|
| DC12024 | ARV-825 Featured | ARV-825 is a BRD4 Inhibitor based on PROTAC technology. ARV-825 binds to BD1 and BD2 of BRD4 with Kds of 90 and 28 nM, respectively. |
|
| DC12614 | Arylsulfonamide 64B | Arylsulfonamide 64B (HIF inhibitor 64B) is a small molecule HIF pathway inhibitor, blocks hypoxia-induced expression of c-Met and CXCR4 and uveal melanoma (UM) cell migration. |
|
| DC20687 | AS 2553627 | AS 2553627 (AS2553627) is a novel potent, selective pan-JAK inhibitor with IC50 of 0.46, 0.30, 0.14 and 2.0 nM for JAK1, JAK2, JAK3 and TYK2, respectively. |
|
| DC8256 | AS 602801(Bentamapimod) Featured | AS 602801(Bentamapimod) is a novel, orally active inhibitor of JNK. |
|
| DC22001 | AS-1269574 Featured | AS-1269574 is a selective, orally available GPR119 agonist with EC50 of 2.5 uM in cell-based cAMP assays. |
|
| DC22002 | AS1928370 | AS1928370 (ASP8370) is a potent, selective, orally available TRPV1 antagonist with IC50 of 0.51 uM, shows no inhibitory effects on TRPV4, TRPA11, and TRPM8 at 10 uM. |
|
| DC22766 | AS-1949490 | AS-1949490 (AS1949490) is a potent, selective SHIP2 inhibitor with IC50 of 0.34/0.62 uM for mouse/human SHIP2. |
|
| DC20682 | AS2521780 | AS2521780 is a potent, selective, orally bioavailable PKCθ inhibitor that inhibits combinant human PKCθ enzyme with IC50 of 0.48 nM, >30-fold higher than other PKC isoforms. |
|
| DC3112 | AS-252424 Featured | AS-252424 is a novel, potent and selective inhibitor of PI3Kγ with IC50 of 33 nM. |
|
| DC20683 | AS2541019 | AS2541019 is a novel potent, selective, orally active PI3Kδ inhibitor with IC50 of 20.1 nM, >100-fold selectivity over other PI3K isoforms. |
|
| DC20684 | AS2677131 | AS2677131(AS 2677131, AS-2677131) is a novel potent, oral PIKfyve inhibitor that selectively decreases c-Rel binding to gene promoters of IL-12p40 and IL-1β, regulates cytokine production through PIKfyve-c-Rel pathway ( IL-12p40 IC50=4 nM). |
|
| DC20035 | AS2717638 Featured | AS2717638 is an oral active lysophosphatidic acid receptor 5 (LPA5) antagonist in rodents. AS2717638 also significantly improves PGE2-, PGF2α-, and AMPA-induced allodynia. |
|
| DC7068 | AS605240 | AS-605240 is a potent and selective inhibitor of PI 3-kinase γ (PI3Kγ) (IC50 = 8 nM). AS-605240 displays 30-fold selectivity over PI3Kδ and PI3Kβ and 7.5-fold selectivity over PI3Kα. |
|
| DC11407 | Asapiprant(BGE-175) Featured | Asapiprant (BGE-175) is a potent and specific antagonist of human PGD2/PTGDR signaling with Ki of 0.44 nM. BGE-175 is currently in a Phase 2 clinical trial to test whether it can prevent disease progression and mortality in older patients hospitalized wit |
|
| DC20622 | Asciminib Featured | Asciminib (ABL-001) is a potent and selective allosteric ABL1 inhibitor with IC50 of 0.25 nM in BCR–ABL1-transformed BaF3 cells. |
|
| DC4169 | ASC-J9 | ASC-J9, is antitumor agent. ASC-J9 suppresses castration-resistant prostate cancer growth via degradation of full-length and splice variant androgen receptors. |
|
| DC21100 | Gusacitinib (ASN-002) Featured | ASN-002 (Gusacitinib, ASN002) is a novel and potent dual inhibitor of SYK/JAK kinases with IC50 of 5-46 nM in biochemical assays. |
|
| DC20109 | ASP-4058 | ASP-4058 is a next-generation, selective and oral bioactive agonist for Sphingosine 1-Phosphate receptors 1 and 5 (S1P1 and S1P5), ameliorates rodent experimental autoimmune encephalomyelitis with a favorable safety profile. |
|
| DC23457 | ASP6432 | ASP6432 (ASP-6432) is a potent and selective antagonist of LPA1 receptor, does-dependently inhibits LPA-stimulated increase in intracellular calcium ion with IC50 of 11 nM. |
|
| DC20693 | ASP9436 | ASP9436 (ASP-9436) is a potent, selective brain penetrant and orally active phosphodiesterase 10A (PDE10A) inhibitor with IC50 of 8.0 nM, >420-fold selectivity over other PDE subtypes. |
|
| DC22003 | Aspacytarabine | Aspacytarabine (Astarabine, BST236) is a cytarabine conjugate that shows anti-neoplastic agents for inhibiting cancer cell growth. . |
|
| DC12360 | Asp-AMS | Asp-AMS, an analogue of aspartyl-adenylate, is an aspartyl-tRNA synthetase inhibitor and also a strong competitive inhibitor of the mitochondrial enzyme. |
|
